TSLA
Tesla
-- 379.280 NVDA
NVIDIA
-- 138.310 RGTI
Rigetti Computing
-- 20.0000 PLTR
Palantir
-- 75.190 AMD
Advanced Micro Devices
-- 120.630 
NEWS
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Xenetic Biosciences (NASDAQ:XBIO)presented positive preclinical data showing the potential of co-administering DNase I with CAR T cells in treating melanoma lung metastasis. The study demonstrated that a single injection of DNase I (10 mg/kg) with EGFR-CAR T cells significantly suppressed metastatic tumor burden and extended survival compared to CAR T cell therapy alone. Key findings showed that DNase I increases tumor-infiltrating T and CAR T cells while reducing immunosuppressive effects. The research supports DNase I's potential as an adjunctive treatment to improve CAR T cell therapy responses, particularly in solid tumors where traditional CAR T cell therapy has shown efficacy.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment